ACR	American College of Rheumatology
ADMA	asymmetric dimethylarginine
AMI	acute myocardial infarction
AnxA1	annexinA1
bDMARDs	biological DMARDs
CANTOS	canakinumab anti-inflammatory outcome study
cGMP	cyclic guanosine monophosphate
CHF	congestive heart failure
CIRT	cardiovascular inflammation reduction trial
COMORA	comorbidities in rheumatoid arthritis
CORRONA	Consortium of Rheumatology Researchers of North America
COX-2	cyclooxygenase-2
CRP	C-reactive protein
csDMARDs	conventional synthetic DMARDs
CVD	cardiovascular disease
CIRT	cardiovascular inflammation reduction trial
DMARDs	disease-modifying antirheumatic drugs
eNOS	endothelial nitric oxide synthase
ESR	erythrocyte sedimentation rate
EULAR	European League Against Rheumatism
FPR2	N-formyl peptide receptor 2
GPCR	G protein-coupled receptor
HDL	high-density lipoprotein
HFpEF	HF with preserved ejection fraction
HFrEF	HF with reduced ejection fraction
ICAM-1	intercellular adhesion molecule-1
IL	interleukin
iNOS	inducible nitric oxide synthase
Jak	Janus kinase
LDL-C	low-density lipoprotein cholesterol
LPS	lipopolysaccharide
LX	lipoxin
MACE	major adverse cardiac events
MCTR1	maresin conjugates in tissue regeneration 1
MHCII	major histocompatibility complex class II
MI	myocardial infarction
MTX	methotrexate
NO	nitric oxide
NSAIDs	nonsteroidal anti-inflammatory drugs
NT-proBNP	N-terminal probrain natriuretic peptide
PKG	protein kinase G
PRECISION	Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen
RA	rheumatoid arthritis
RvD3	resolvin D3
RvT	13-series resolvins
SPMs	specialised pro-resolving mediators
TGF	transforming growth factor
TNF	tumour necrosis factor
tsDMARDs	targeted synthetic DMARDs